주목 시장 분석 : 헌팅턴병
Market Spotlight: Huntington´s Disease
상품코드 : 573554
리서치사 : Datamonitor Healthcare
발행일 : 2020년 08월
페이지 정보 : 영문 29 Pages
US $ 1,318 ₩ 1,556,000
PDF by E-mail (Single User License)


한글목차

전세계 30세 이상 인구 중 헌팅턴병 유병자수는 2017년 159,410명에 달한 것으로 추정되며, 2026년에는 184,950명까지 증가할 것으로 예측됩니다. 지역별로는 북미 유병자수가 가장 많으며, 아시아가 가장 적은 것으로 보입니다. 임상개발 중인 약제의 대부분은 2상 임상시험 중이며, 2종의 약제가 3상 임상시험 단계입니다. 표적으로는 huntingtin, vesicular monamine transporters, p38 MAP kinase, SIRT1, vasopressin receptors, semaphorin 4D/CD100, aryl hydrocarbon receptor, NMDA glutamate receptor, PPAR delta, PPAR gamma 등이 있습니다. 파이프라인 의약품의 대부분은 경구제이며, 그 외에는 골수강내 제제, 정맥내 제제, 뇌내/뇌실내 제제 등이 있습니다. 지역별로 임상시험은 미국에서 가장 많이 행해지고 있고, EU에서는 영국이 최고 지위를 차지하고 있습니다.

세계의 헌팅턴병(Huntington's Disease) 치료제 시장을 조사했으며, 질환의 배경 및 개요, 유병자수 10개년 예측, 파이프라인 의약품 및 출시 의약품 개요, 임상시험 상황, 라이선싱/자산 인수 등의 주요 거래 동향, 특허 정보, 주요 약제 매출 예측 등을 정리했습니다.

개요

요점

질환의 배경

치료

역학

출시 의약품

파이프라인 의약품

최근 이벤트 및 애널리스트의 견해

향후 전개

규제 전개

라이선싱 및 자산 취득 계약

원특허권(Parent Patent)

매출 기회

임상시험 환경

문헌

부록

LSH 20.02.12

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

영문 목차

영문목차

Huntington's disease (HD) is a rare disorder of the central nervous system (CNS) which causes the degeneration of nerve cells. It is an autosomal dominant disease characterized by involuntary choreatic movements, psychiatric and behavioral disturbances, and dementia. The mean age of symptom onset is 30-50 years. HD is caused by the presence of >40 cytosine-adenine-guanine (CAG) repeats within the Huntingtin gene. The length of the CAG repeats is inversely associated with the age of disease onset - the longer the repeat, the earlier the onset. In the case of juvenile HD (JHD), the length of the repeat is >55 and the disease's symptoms are seen in patients aged <20 years. Learning disabilities and behavioral disturbances are the first symptoms in patients with JHD.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were 77,200 prevalent cases of Huntington's disease (HD) in adults aged 30 years and older worldwide, and forecasts that number to increase to 87,700 prevalent cases by 2028.

Northern America is estimated to have the highest disease prevalence (0.0073%), while Asia has the lowest prevalence (0.0004%).

Teva's Austedo and Bausch Health's Xenazine, which target vesicular monamine transporters, are the only marketed drugs for HD. These drugs are administered via the oral route.

The majority of industry-sponsored drugs in active clinical development for HD are in Phase II, with two drugs in Phase III. Therapies in active clinical development for HD focus on targets such as huntingtin, vesicular monamine transporters, p38 MAP kinase, SIRT1, vasopressin receptors, semaphorin 4D/CD100, NMDA glutamate receptor, PPAR delta, and PPAR gamma. The majority of the pipeline drugs are administered via the oral route, with the remainder being intrathecal, intravenous, and intracerebral/cerebroventricular formulations.

High-impact upcoming events for drugs in the HD space comprise topline Phase Ib/IIa trial results for WVE-120101, topline Phase I/II trial results for AMT-130, topline Phase IIa trial results for ANX-005, and topline Phase III trial results for Ingrezza and tominersen.

The overall likelihood of approval of a Phase I neurodegenerative asset is 7.9%, and the average probability a drug advances from Phase III is 49.5%. Drugs, on average, take 10.9 years from Phase I to approval, compared to 9.8 years in the overall neurology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for HD have been in the early and midphases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV.

The US has a substantial lead in the number of HD clinical trials globally, while the UK leads the major European markets. Clinical trial activity in the HD space is dominated by completed trials. Pfizer and Teva have the highest number of completed clinical trials for HD, with 14 trials each.

Pfizer and Teva lead industry sponsors with the highest overall number of clinical trials for HD.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

LIST OF TABLES

(주)글로벌인포메이션 02-2025-2992 koreainfo@gii.co.jp
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기